Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19
Latest Information Update: 23 Aug 2024
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 21 Aug 2024 Planned End Date changed from 17 Feb 2025 to 17 Feb 2026.
- 21 Aug 2024 Planned primary completion date changed from 18 Aug 2024 to 18 Aug 2025.
- 11 Jan 2022 Results of an analysis to compare the immunogenicity of using BNT162b2 and CoronaVac as a third dose for adults with low antibody response to two doses of CoronaVac published in the American Journal of Respiratory and Critical Care Medicine